Literature DB >> 25495407

SNPs and taxane toxicity in breast cancer patients.

Virginia Bosó1, María José Herrero, Ana Santaballa, Laura Palomar, Juan E Megias, Helena de la Cueva, Luis Rojas, María Remedios Marqués, José Luis Poveda, Joaquin Montalar, Salvador F Aliño.   

Abstract

AIM: In order to identify genetic variants associated with taxanes toxicity, a panel with 47 SNPs in 20 genes involved in taxane pathways was designed. PATIENTS &
METHODS: Genomic DNA of 113 breast cancer patients was analyzed (70 taking docetaxel, 43 taking paclitaxel).
RESULTS: Two SNPs associated with docetaxel toxicity were identified: CYP3A4*1B with infusion-related reactions; and ERCC1 Gln504Lys with mucositis (p≤0.01). Regarding paclitaxel toxicity: CYP2C8 HapC and CYP2C8 rs1934951 were associated with anemia; and ERCC1 Gln504Lys with neuropathy (p≤0.01).
CONCLUSION: Genes involved in DNA repair mechanisms and reactive oxygen species levels influence taxane toxicity in cancer patients treated with chemotherapy schemes not containing platinum. These findings could lead to better treatment selection for breast cancer patients.

Entities:  

Keywords:  breast neoplasms; drug-related adverse reactions; genetic polymorphism; pharmacogenetics; taxoids

Mesh:

Substances:

Year:  2014        PMID: 25495407     DOI: 10.2217/pgs.14.127

Source DB:  PubMed          Journal:  Pharmacogenomics        ISSN: 1462-2416            Impact factor:   2.533


  19 in total

1.  Genome-wide meta-analyses identifies novel taxane-induced peripheral neuropathy-associated loci.

Authors:  Lara E Sucheston-Campbell; Alyssa I Clay-Gilmour; William E Barlow; G Thomas Budd; Daniel O Stram; Christopher A Haiman; Xin Sheng; Li Yan; Gary Zirpoli; Song Yao; Chen Jiang; Kouros Owzar; Dawn Hershman; Kathy S Albain; Daniel F Hayes; Halle C Moore; Timothy J Hobday; James A Stewart; Abbas Rizvi; Claudine Isaacs; Muhammad Salim; Jule R Gralow; Gabriel N Hortobagyi; Robert B Livingston; Deanna L Kroetz; Christine B Ambrosone
Journal:  Pharmacogenet Genomics       Date:  2018-02       Impact factor: 2.089

2.  Genome-Wide Association Studies for Taxane-Induced Peripheral Neuropathy in ECOG-5103 and ECOG-1199.

Authors:  Bryan P Schneider; Lang Li; Milan Radovich; Tatiana Foroud; George W Sledge; Fei Shen; Kathy D Miller; David A Flockhart; Guanglong Jiang; Gail Vance; Laura Gardner; Matteo Vatta; Shaochun Bai; Dongbing Lai; Daniel Koller; Fengmin Zhao; Anne O'Neill; Mary Lou Smith; Elda Railey; Carol White; Ann Partridge; Joseph Sparano; Nancy E Davidson
Journal:  Clin Cancer Res       Date:  2015-07-02       Impact factor: 12.531

3.  PET Imaging on Dynamic Metabolic Changes after Combination Therapy of Paclitaxel and the Traditional Chinese Medicine in Breast Cancer-Bearing Mice.

Authors:  Yao Chen; Ling Wang; Hao Liu; Fahuan Song; Caiyun Xu; Kai Zhang; Qing Chen; Shuang Wu; Yunqi Zhu; Ying Dong; Min Zhou; Hong Zhang; Mei Tian
Journal:  Mol Imaging Biol       Date:  2018-04       Impact factor: 3.488

4.  Pharmacogenetics of taxane-induced neurotoxicity in breast cancer: Systematic review and meta-analysis.

Authors:  Alberto Guijosa; Ana Freyria; Jose Rodrigo Espinosa-Fernandez; Francisco J Estrada-Mena; Ana Sofía Armenta-Quiroga; Maria Fernanda Ortega-Treviño; Rodrigo Catalán; Bani Antonio-Aguirre; Cynthia Villarreal-Garza; Andric C Perez-Ortiz
Journal:  Clin Transl Sci       Date:  2022-08-17       Impact factor: 4.438

5.  Management of Side Effects in the Personalized Medicine Era: Chemotherapy-Induced Peripheral Neurotoxicity.

Authors:  Eleonora Pozzi; Paola Alberti
Journal:  Methods Mol Biol       Date:  2022

6.  Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer.

Authors:  John K Chan; Mark F Brady; Richard T Penson; Helen Huang; Michael J Birrer; Joan L Walker; Paul A DiSilvestro; Stephen C Rubin; Lainie P Martin; Susan A Davidson; Warner K Huh; David M O'Malley; Matthew P Boente; Helen Michael; Bradley J Monk
Journal:  N Engl J Med       Date:  2016-02-25       Impact factor: 91.245

7.  Weekly Carboplatin and Paclitaxel: A Retrospective Comparison with the Three-Weekly Schedule in First-Line Treatment of Ovarian Cancer.

Authors:  Tamar Safra; Barliz Waissengrin; Talya Levy; Ellie Leidner; Rotem Merose; Diana Matceyevsky; Dan Grisaru; Ido Laskov; Nadav Mishaan; Rotem Shayzaf; Ido Wolf
Journal:  Oncologist       Date:  2020-08-12

8.  Association of single nucleotide polymorphisms in the MVP gene with platinum resistance and survival in patients with epithelial ovarian cancer.

Authors:  Ya-Nan Zhao; Dong-Ning He; Ya-DI Wang; Jun-Jie Li; Min-Wen Ha
Journal:  Oncol Lett       Date:  2016-03-08       Impact factor: 2.967

9.  An Example of Personalized Treatment in HR+ HER2+ Long Survivor Breast Cancer Patient (Case Report).

Authors:  Martina Panebianco; Beatrice Taurelli Salimbeni; Michela Roberto; Paolo Marchetti
Journal:  Curr Oncol       Date:  2021-05-25       Impact factor: 3.677

10.  Polymorphism of CYP3A4 and ABCB1 genes increase the risk of neuropathy in breast cancer patients treated with paclitaxel and docetaxel.

Authors:  Tulay Kus; Gokmen Aktas; Mehmet Emin Kalender; Abdullah Tuncay Demiryurek; Mustafa Ulasli; Serdar Oztuzcu; Alper Sevinc; Seval Kul; Celaletdin Camci
Journal:  Onco Targets Ther       Date:  2016-08-12       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.